97 related articles for article (PubMed ID: 14651725)
1. The effects of KT3-671, a new angiotensin II (AT 1) receptor blocker in mild to moderate hypertension.
Patterson D; Webster J; McInnes G; Brady A; MacDonald T
Br J Clin Pharmacol; 2003 Nov; 56(5):513-9. PubMed ID: 14651725
[TBL] [Abstract][Full Text] [Related]
2. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
Chrysant SG; Marbury TC; Robinson TD
J Hum Hypertens; 2003 Jun; 17(6):425-32. PubMed ID: 12764406
[TBL] [Abstract][Full Text] [Related]
5. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
[TBL] [Abstract][Full Text] [Related]
7. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
[TBL] [Abstract][Full Text] [Related]
8. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Fosinopril/Hydrochlorothiazide Investigators.
Guthrie R; Reggi DR; Plesher MM; Saini RK; Battikha JP
Am J Hypertens; 1996 Apr; 9(4 Pt 1):306-11. PubMed ID: 8722432
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group.
Lacourcière Y; Pool JL; Svetkey L; Gradman AH; Larochelle P; de Champlain J; Smith WB
Am J Hypertens; 1998 Apr; 11(4 Pt 1):454-61. PubMed ID: 9607384
[TBL] [Abstract][Full Text] [Related]
12. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
Radauceanu A; Boivin JM; Bernaud C; Fay R; Zannad F;
Fundam Clin Pharmacol; 2004 Aug; 18(4):483-91. PubMed ID: 15312156
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
Punzi HA
Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985
[TBL] [Abstract][Full Text] [Related]
14. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
Luque Otero M; Martell Claros N;
Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
[TBL] [Abstract][Full Text] [Related]
15. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
[TBL] [Abstract][Full Text] [Related]
16. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
Lacourcière Y; Neutel JM; Schumacher H
Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
[TBL] [Abstract][Full Text] [Related]
18. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Littlejohn T; Mroczek W; Marbury T; VanderMaelen CP; Dubiel RF
Can J Cardiol; 2000 Sep; 16(9):1123-32. PubMed ID: 11021956
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.
Hedner T; Himmelmann A
J Hypertens; 1999 Jan; 17(1):129-36. PubMed ID: 10100104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
